These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Besifloxacin ophthalmic suspension 0.6% in patients with bacterial conjunctivitis: A multicenter, prospective, randomized, double-masked, vehicle-controlled, 5-day efficacy and safety study. Karpecki P; Depaolis M; Hunter JA; White EM; Rigel L; Brunner LS; Usner DW; Paterno MR; Comstock TL Clin Ther; 2009 Mar; 31(3):514-26. PubMed ID: 19393842 [TBL] [Abstract][Full Text] [Related]
7. Human aqueous humor concentrations of besifloxacin, moxifloxacin, and gatifloxacin after topical ocular application. Donnenfeld ED; Comstock TL; Proksch JW J Cataract Refract Surg; 2011 Jun; 37(6):1082-9. PubMed ID: 21596251 [TBL] [Abstract][Full Text] [Related]
8. Effect of dosing interval on the efficacy of topical ophthalmic gatifloxacin against Enterococcus faecalis in an in vitro pharmacokinetic model simulating the local eye compartment. Kozai S; Wada T; Kida T; Tajika T; Sakaki H; Ohtori A Int J Antimicrob Agents; 2009 Dec; 34(6):561-5. PubMed ID: 19782539 [TBL] [Abstract][Full Text] [Related]
9. Besifloxacin, a new ophthalmic fluoroquinolone for the treatment of bacterial conjunctivitis. Bertino JS; Zhang JZ Expert Opin Pharmacother; 2009 Oct; 10(15):2545-54. PubMed ID: 19743941 [TBL] [Abstract][Full Text] [Related]
10. Efficacy and tolerability of besifloxacin ophthalmic suspension 0.6% administered twice daily for 3 days in the treatment of bacterial conjunctivitis: a multicenter, randomized, double-masked, vehicle-controlled, parallel-group study in adults and children. Silverstein BE; Allaire C; Bateman KM; Gearinger LS; Morris TW; Comstock TL Clin Ther; 2011 Jan; 33(1):13-26. PubMed ID: 21397770 [TBL] [Abstract][Full Text] [Related]
11. Fluoroquinolone benchmarking in relation to pharmacokinetic and pharmacodynamic parameters. Paladino JA; Callen WA J Antimicrob Chemother; 2003 May; 51 Suppl 1():43-7. PubMed ID: 12702703 [TBL] [Abstract][Full Text] [Related]
12. Besifloxacin, a novel fluoroquinolone antimicrobial agent, exhibits potent inhibition of pro-inflammatory cytokines in human THP-1 monocytes. Zhang JZ; Ward KW J Antimicrob Chemother; 2008 Jan; 61(1):111-6. PubMed ID: 17965029 [TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics, pharmacodynamics and therapeutics of pradofloxacin in the dog and cat. Lees P J Vet Pharmacol Ther; 2013 Jun; 36(3):209-21. PubMed ID: 23406008 [TBL] [Abstract][Full Text] [Related]
15. Safety of moxifloxacin as shown in animal and in vitro studies. McGee DH; Holt WF; Kastner PR; Rice RL Surv Ophthalmol; 2005 Nov; 50 Suppl 1():S46-54. PubMed ID: 16257310 [TBL] [Abstract][Full Text] [Related]
16. Reliability of phototoxic tests of fluoroquinolones in vitro. Zhang T; Li JL; Ma XC; Xin J; Tu ZH Acta Pharmacol Sin; 2003 May; 24(5):453-9. PubMed ID: 12740182 [TBL] [Abstract][Full Text] [Related]
17. Clinical implications of pharmacokinetics and pharmacodynamics of fluoroquinolones. Wispelwey B Clin Infect Dis; 2005 Jul; 41 Suppl 2():S127-35. PubMed ID: 15942879 [TBL] [Abstract][Full Text] [Related]
18. Analysis of the safety and pharmacodynamics of human fibrinogen concentrate in animals. Beyerle A; Nolte MW; Solomon C; Herzog E; Dickneite G Toxicol Appl Pharmacol; 2014 Oct; 280(1):70-7. PubMed ID: 25102310 [TBL] [Abstract][Full Text] [Related]
19. In vivo ocular efficacy profile of mapracorat, a novel selective glucocorticoid receptor agonist, in rabbit models of ocular disease. Shafiee A; Bucolo C; Budzynski E; Ward KW; López FJ Invest Ophthalmol Vis Sci; 2011 Mar; 52(3):1422-30. PubMed ID: 20881303 [TBL] [Abstract][Full Text] [Related]
20. Evaluation of gatifloxacin pharmacokinetics and pharmacodynamics in severely ill adults in a medical Intensive Care Unit. Fish DN Int J Antimicrob Agents; 2007 Jun; 29(6):715-23. PubMed ID: 17433631 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]